VYNE Therapeutics Announces Special Cash Dividend Of $0.38/Share

8-K/A filing — Yarrow Bioscience, Inc. (VYNE)

Filed: 2026-08-13 AccNo: 0001104659-26-095925 Size: 8 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K filing — Yarrow Bioscience, Inc. (VYNE)

Filed: 2026-07-28 AccNo: 0001104659-26-087601 Size: 15 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Yarrow Bioscience And VYNE Therapeutics Compete Merger With Previously Announced Private Financings Totaling ~$200M; To Operate As Yarrow Bioscience And Trade On Nasdaq Capital Market From July 28 Under Ticker Symbol 'YARW'

Yarrow is advancing YB-101—a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves’ disease ("GD") and thyroid eye disease ("TED")Dosing

VYNE Therapeutics shares are trading lower after the company announced a 1-for-50 reverse stock split.